--- title: "Allogene Therapeutics (NASDAQ:ALLO) Reaches New 1-Year High - Here's What Happened" type: "News" locale: "en" url: "https://longbridge.com/en/news/276920198.md" description: "Allogene Therapeutics (NASDAQ:ALLO) reached a new 52-week high of $2.57 during trading, closing at $2.4650 with a volume of over 2 million shares. Analysts have given a \"buy\" rating with a target price of $8.00, while the average rating is a \"Moderate Buy\" with a consensus target of $8.40. Insider trading saw CEO David D. Chang and EVP Zachary Roberts sell shares, reducing their stakes. Institutional investors hold 83.63% of the stock, indicating strong interest in the company, which focuses on developing allogeneic CAR T therapies for cancer treatment." datetime: "2026-02-25T17:22:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276920198.md) - [en](https://longbridge.com/en/news/276920198.md) - [zh-HK](https://longbridge.com/zh-HK/news/276920198.md) --- # Allogene Therapeutics (NASDAQ:ALLO) Reaches New 1-Year High - Here's What Happened Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) hit a new 52-week high during trading on Wednesday . The stock traded as high as $2.57 and last traded at $2.4650, with a volume of 2017092 shares trading hands. The stock had previously closed at $2.29. Get **Allogene Therapeutics** alerts: ## Wall Street Analysts Forecast Growth - 3 Stocks With Sky-High Short Interest Levels Several analysts have recently commented on ALLO shares. UBS Group began coverage on shares of Allogene Therapeutics in a research report on Wednesday, January 7th. They set a "buy" rating and a $8.00 price objective on the stock. Citigroup upgraded shares of Allogene Therapeutics from a "market perform" rating to an "outperform" rating in a research note on Friday, January 9th. Wall Street Zen raised Allogene Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday. Finally, Citizens Jmp raised shares of Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 target price for the company in a report on Friday, January 9th. Ten research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Allogene Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $8.40. **Check Out Our Latest Analysis on ALLO** ## Allogene Therapeutics Trading Up 5.5% - 2 Downgrades in Healthcare You Might Want to Buy The firm's fifty day moving average price is $1.64 and its 200 day moving average price is $1.38. The stock has a market capitalization of $542.72 million, a price-to-earnings ratio of -2.46 and a beta of 0.60. ## Insider Activity at Allogene Therapeutics In other Allogene Therapeutics news, CEO David D. Chang sold 95,269 shares of Allogene Therapeutics stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $1.80, for a total value of $171,484.20. Following the transaction, the chief executive officer owned 5,185,862 shares in the company, valued at $9,334,551.60. This trade represents a 1.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Zachary Roberts sold 35,700 shares of the company's stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $1.77, for a total value of $63,189.00. Following the sale, the executive vice president owned 581,166 shares of the company's stock, valued at $1,028,663.82. This represents a 5.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 215,855 shares of company stock worth $378,426. 13.20% of the stock is currently owned by company insiders. ## Institutional Investors Weigh In On Allogene Therapeutics A number of large investors have recently added to or reduced their stakes in ALLO. Savant Capital LLC acquired a new stake in shares of Allogene Therapeutics in the third quarter worth $27,000. Russell Investments Group Ltd. lifted its position in Allogene Therapeutics by 11,159.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 21,844 shares of the company's stock worth $27,000 after buying an additional 21,650 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in shares of Allogene Therapeutics during the 3rd quarter worth about $30,000. Caitong International Asset Management Co. Ltd raised its holdings in Allogene Therapeutics by 5,267.6% during the third quarter. Caitong International Asset Management Co. Ltd now owns 24,047 shares of the company's stock worth $30,000 after acquiring an additional 23,599 shares in the last quarter. Finally, Brighton Jones LLC grew its stake in Allogene Therapeutics by 81.6% in the third quarter. Brighton Jones LLC now owns 25,168 shares of the company's stock valued at $31,000 after purchasing an additional 11,311 shares in the last quarter. Institutional investors own 83.63% of the company's stock. ## Allogene Therapeutics Company Profile (Get Free Report) Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance. The company's pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers. ## Featured Articles - Five stocks we like better than Allogene Therapeutics - The gold chart Wall Street is terrified of… - America’s 1776 happening again - This makes me furious - Buy this Gold Stock Before May 2026 - What a Former CIA Agent Knows About the Coming Collapse _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Allogene Therapeutics Right Now? Before you consider Allogene Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allogene Therapeutics wasn't on the list. While Allogene Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [ALLO.US](https://longbridge.com/en/quote/ALLO.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) ## Related News & Research - [BUZZ-Allogene tumbles on $175 mln stock offering after cancer therapy data](https://longbridge.com/en/news/282722450.md) - [Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform](https://longbridge.com/en/news/282587297.md) - [Allogene's blood cancer therapy delays cancer relapse in mid-stage study](https://longbridge.com/en/news/282537381.md) - [Gossamer Bio Receives Nasdaq Minimum Bid Price Deficiency Notice](https://longbridge.com/en/news/282247265.md) - [FDA Rejection Sparks Questions On Replimune Drug Approval Path](https://longbridge.com/en/news/282577359.md)